Ruplizumab Biosimilar

Ruplizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40LG, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Ruplizumab is a humanized monoclonal antibody that has been used as an immunosuppressant and is a component of Antova. Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells and monocytes.

Target	CD40LG
Research Area	Humanized Monoclonal Antibodies, Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
Buffer	0.01 M PBS, pH 7.4.
CAS Number	220651-94-5
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on CD40LG

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue